VERAXA Biotech Announces Regulatory Progress with its BiTAC-TCE Development Plan
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA;…
VERAXA Biotech AG Appoints Carl von Halem as InterimChief Financial Officer and Successor to Torsten Brgermeister
ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA;…
